Aprea Therapeutics, Inc. Common stock (APRE)
Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer. The company specializes in deploying its proprietary DNA damage response (DDR) pathway inhibitors to treat various malignancies, aiming to improve outcomes for patients with difficult-to-treat cancers.
Company News
Aprea Therapeutics reported positive preclinical and early-stage clinical data for its next-generation WEE1 inhibitor, APR-1051, in treating HPV-positive head and neck squamous cell carcinoma. The drug showed potent single-agent activity and enhanced synergy with anti-PD-1 therapies in preclinical models, and demonstrated early disease control in...
The approval is based on data from a phase II/III study, which showed that treatment with Jazz's (JAZZ) Enrylaze achieved sustained asparagine activity in two cancer indications.
The Dow Jones closed higher by over 160 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider tra...
4 Biotech Penny Stocks To Watch, January 2023 The post Best Penny Stocks To Buy? 4 To Watch In January 2023 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.